Methylene Blue: From Hospital Drug to Longevity Trend: What It Does and Why Self-Dosing Is Risky

The video is short: a glass of water, a dropper, a swirl of ink-dark blue, a confident sip. Millions of people watched some version of it in 2025, and the comments filled with the same question in different words. Should I be doing this too?

As of mid-2025, searches for methylene blue have climbed to levels this century-old compound has never seen. Wellness podcasts call it a mitochondrial supercharger. Longevity forums trade tips about turquoise-tinted urine as if it were a badge. Yet the medicine behind the trend has spent most of its life in a very different setting, drawn up into syringes in emergency departments and operating rooms for a narrow and genuinely life-saving purpose.

That gap between the hospital drug and the kitchen-counter ritual is where this story lives. What follows is what the evidence supports, where it thins out, and why pharmacologists who admire this molecule still wince when they see it in a water glass.

Why is methylene blue trending right now?

Trends in health rarely start with a study. They start with a story, and methylene blue has a good one. It was the first fully synthetic drug ever used in medicine, dating to the 1870s as a textile dye and the 1890s as a malaria treatment. It stains cells for microscopy, colors urine an unmistakable blue-green, and has a mechanism that touches the mitochondria, the tiny structures inside cells that turn food into usable energy. That combination of history, visible effect and a plausible biological hook is catnip for the longevity community.

The spark in early 2025 was a series of viral clips showing well-known figures adding drops of the dye to their drinks. Influencers followed, pairing the footage with claims about sharper focus, better mood and slower aging. Search interest jumped within weeks, and products labeled for aquarium use or as “research chemicals” began appearing in unboxing videos.

Two features make this trend distinct from, say, the creatine or magnesium waves. First, methylene blue is not a nutrient. Nobody is deficient in it, and the body has no requirement for it. Second, it is a regulated prescription medicine in the United States with a documented list of drug interactions serious enough to carry a formal safety warning. That is a different category of decision from adding a vitamin.

None of this means the science is empty. Researchers have studied methylene blue for decades in neurology, infectious disease and critical care, and some of that work is intriguing. The honest position is narrower than either the enthusiasts or the dismissers suggest, and the rest of this article walks through it one claim at a time.

What changed recently: from a 2016 approval to 2025 viral drops

A few dated facts anchor the current moment.

For most of the twentieth century, hospitals used methylene blue under older regulatory pathways without a modern approval. That changed in 2016, when the U.S. Food and Drug Administration approved a pharmaceutical-grade intravenous formulation specifically for acquired methemoglobinemia, a condition in which hemoglobin is chemically altered so it can no longer carry oxygen properly. The approval mattered because it set purity standards and formalized the labeling, including warnings that had accumulated over years of case reports.

One of those warnings dates to 2011, when the FDA alerted clinicians that methylene blue given with serotonin-active medicines, particularly the SSRI and SNRI antidepressants, could trigger serotonin syndrome, a potentially life-threatening reaction caused by too much serotonin activity in the nervous system. The StatPearls pharmacology review and the peer-reviewed “Methylene Blue: Revisited” article both describe this interaction as a defining safety issue for the drug.

On the research side, a modified form of the molecule, hydromethylthionine, was tested in large phase 3 Alzheimer’s disease trials between 2016 and 2023. Those trials did not meet their primary goals, though the sponsor reported secondary findings that keep the question open. It is worth stressing that the study drug was a derivative, not the dye sold in dropper bottles.

Then came 2025. No new trial, approval or guideline drove the surge; a handful of viral videos did. Regulators have not approved methylene blue as a dietary supplement, a nootropic or an anti-aging product, and products marketed for those purposes sit outside any approved use. That regulatory status is not a technicality. It means no agency has reviewed those products for purity, strength or safety in the way it reviews the hospital formulation.

What is methylene blue used for in hospitals?

Ask an emergency physician about methylene blue and you will hear one word first: methemoglobinemia. Certain drugs and chemicals, including some local anesthetics, the antibiotic dapsone, nitrites and aniline dyes, can oxidize the iron in hemoglobin so it cannot release oxygen to tissues. Patients turn a dusky gray-blue, feel short of breath and, at high levels, can develop seizures or heart rhythm problems. Methylene blue reverses the chemistry, usually within an hour. According to MedlinePlus and the StatPearls review, it is the standard antidote when methemoglobin levels are high or the patient is symptomatic.

Beyond that headline indication, the drug has several smaller hospital roles, most of them supported by case series and small trials rather than large randomized studies:

• Vasoplegic syndrome. After cardiac surgery or in septic shock, blood vessels sometimes relax so profoundly that blood pressure collapses despite standard medicines. Methylene blue blocks part of the nitric oxide pathway that drives this relaxation and can raise blood pressure. Intensive care teams use it as a rescue option.
• Ifosfamide encephalopathy. This chemotherapy drug occasionally causes confusion and drowsiness; methylene blue has been reported to help in small series.
• Surgical dye. Surgeons inject it to trace the ureters, find leaks in the bowel or bladder, and map lymph nodes.
• Diagnostic staining. Pathologists and endoscopists use it to make abnormal tissue easier to see.

Every one of these uses happens under monitoring, with a known dose calculated by a clinician who has checked the patient’s medication list and, where relevant, enzyme status. The drug’s value in these settings is real. The setting is the point.

How does methylene blue work in the body?

Methylene blue is what chemists call a redox agent, meaning it can accept electrons and hand them off again, shuttling between a blue oxidized form and a colorless reduced form. Almost everything interesting about it flows from that trick.

In methemoglobinemia, the drug acts as a middleman. Red blood cells reduce methylene blue to its colorless form using an enzyme pathway that depends on NADPH, a cellular energy carrier. The reduced dye then donates electrons to the damaged hemoglobin, restoring its ability to carry oxygen. This is why the antidote fails in people with G6PD deficiency, an inherited enzyme shortage: without enough NADPH, the shuttle stalls, and the oxidizing dye can instead damage red cells directly.

Inside mitochondria, methylene blue can bypass a damaged step in the electron transport chain, the assembly line that produces most of the cell’s energy currency. In laboratory dishes, this appears to improve energy output and reduce the leak of harmful reactive oxygen species. This finding is the seed of nearly every longevity claim, and it is a legitimate observation in cells and animals.

Two more actions matter for safety. Methylene blue inhibits monoamine oxidase A, an enzyme that breaks down serotonin; that is the mechanism behind serotonin syndrome when it is combined with antidepressants. It also inhibits nitric oxide signaling in blood vessels, which is useful in shock but can raise blood pressure in someone who does not need it.

The same molecule, then, is antidote, energy shuttle, antidepressant-interacting enzyme blocker and vasoconstrictor at once. Which face you see depends on dose, route and the person taking it. That is exactly why the pharmacology reviews describe it as a drug with a narrow window rather than a gentle tonic.

What the evidence actually says about methylene blue benefits

Evidence in medicine comes in tiers. Randomized controlled trials, where participants are assigned by chance to drug or placebo, sit at the top. Observational studies and case series come next. Animal and cell studies, however elegant, sit below because most findings at that level never translate to people. Here is where each methylene blue claim lands.

Methemoglobinemia: decades of consistent clinical experience, physiological measurements showing rapid reversal, and regulatory approval. No modern placebo trial exists because withholding treatment would be unethical. Strength: strong, by clinical consensus.

Vasoplegia and shock: several small randomized trials and many observational reports show blood pressure rises. Effects on survival are unproven. Strength: moderate for the blood pressure effect, weak for outcomes.

Malaria: randomized trials in Africa, mostly in combination regimens, show the drug reduces the parasite forms that spread infection. It remains investigational and is not part of standard treatment. Strength: moderate but preliminary.

Memory in healthy adults: a single small imaging study of roughly two dozen volunteers found that one dose increased brain activity on scans and produced a modest improvement on a memory task. No study has tested repeated use or real-world benefit. Strength: very weak.

Alzheimer’s disease: phase 3 trials of a derivative did not meet their primary endpoints. Strength: negative to inconclusive.

Longevity, anti-aging, mitochondrial health: cell cultures and rodent studies only. No human trial has measured lifespan, biological aging markers or long-term safety. Strength: preclinical, meaning no direct human evidence.

Read across that list and a pattern appears. The uses with strong evidence are acute, supervised and specific. The uses that fuel the trend have the least evidence and the most exposure, because they involve healthy people taking a drug day after day for years.

Does methylene blue help the brain, memory or Alzheimer's?

This is the claim with the most scientific scaffolding, so it deserves an honest look rather than a quick dismissal.

The biological rationale is coherent. Neurons are energy-hungry, mitochondrial function declines in many brain diseases, and methylene blue can support electron flow in stressed mitochondria. In rodents, low doses have improved performance on maze tasks and reduced markers of damage after experimental stroke. In cell models, the compound interferes with the clumping of tau, the protein that forms tangles in Alzheimer’s disease. Those findings are why serious research groups spent years and considerable money testing it.

The human results have been humbling. The largest program used hydromethylthionine, a chemically modified version designed to be better tolerated. Two phase 3 trials published in 2016 found no significant benefit over placebo on cognition or daily function for the main comparison. A later trial reported in 2022 and 2023 again missed its primary endpoint, though the sponsor highlighted slower decline in some pre-specified subgroups. Independent experts have generally described the overall picture as unproven.

For healthy people hoping for sharper focus, the evidence is thinner still. The often-cited imaging study enrolled about 26 volunteers, gave a single dose, and measured a brief memory task in a scanner. That design cannot tell anyone whether taking the dye for months improves work performance, mood or the chance of dementia, and it says nothing about cumulative side effects.

Where does that leave a reader who is worried about memory? With the interventions that do have randomized trial support: managing blood pressure, staying physically active, treating hearing loss, sleeping enough and keeping socially engaged. Methylene blue remains a research question, and anyone with cognitive concerns should raise them with a clinician rather than a dropper bottle.

Methylene blue and longevity: the mitochondria claim, examined

The longevity pitch usually goes like this: aging is mitochondrial decline, methylene blue rescues mitochondria, therefore methylene blue slows aging. Each link in that chain is weaker than the last.

Mitochondrial dysfunction does accumulate with age and contributes to frailty, muscle loss and some neurodegenerative diseases. That part is mainstream science. The second link is where the evidence narrows. In cultured human skin cells, methylene blue has extended the number of times cells can divide and reduced markers of cellular senescence, the state in which cells stop dividing and secrete inflammatory signals. In some mouse studies, treated animals showed better exercise capacity or memory late in life. These are genuine results published in peer-reviewed journals.

The third link does not exist yet. No human trial has measured whether methylene blue changes lifespan, healthspan, epigenetic age or any validated aging biomarker. The compounds that looked most promising in mice for longevity, from resveratrol to various antioxidants, have a long record of failing to deliver in people, partly because human aging is slower, more varied and shaped by dozens of pathways at once.

There is also a dose paradox that longevity content tends to skip. Methylene blue helps mitochondria at low concentrations and harms them at higher ones, because the same electron-shuttling ability that supports energy production can generate oxidative stress when the system is flooded. Cell studies show this hormetic curve clearly. Translating a beneficial concentration from a petri dish to a human bloodstream, then maintaining it daily for decades without tipping into the harmful range, is not something anyone has demonstrated.

A fair summary: the mitochondrial story is scientifically interesting and worth studying in trials. It is not a reason for a healthy person to take a prescription oxidizing agent every morning.

Is methylene blue safe to take daily?

Nobody knows, and that answer is more precise than it sounds.

Safety data for methylene blue comes almost entirely from short exposures: one or two intravenous doses in a hospital, a few days of oral use in malaria trials, or a single dose in a research study. The Alzheimer’s trials of the modified derivative did follow participants for months and reported gastrointestinal upset, urinary symptoms, blue-tinged urine and, in some participants, lowered blood counts. Those trials used a related but distinct compound, so the results only partially transfer.

What does not exist is a study of healthy adults taking the dye daily for years, which is exactly what the trend proposes. Long-term effects on the gut microbiome, the kidneys that excrete the drug, the retina, or the balance of serotonin in the brain have not been measured. Absence of evidence is not evidence of safety when the exposure has never been studied.

Several known properties argue for caution with repeated use. Methylene blue inhibits monoamine oxidase, an enzyme that regulates mood chemistry, and long-term inhibition is not a trivial change. It is photosensitizing, meaning it can make skin and eyes more reactive to light. It accumulates in tissues, which is why it stains, and daily intake adds to that load.

Then there is the product problem. The hospital formulation is manufactured to pharmaceutical standards with verified concentration and purity. Products labeled for aquariums, laboratories or “research” are not, and analyses of such products have found variable strength and contaminants. A daily habit built on an unverified product multiplies whatever risk the molecule itself carries.

Anyone considering regular use for any reason should treat it as a prescription decision, made with a clinician who can review medications, check enzyme status where relevant, and monitor for problems.

Methylene blue side effects: from blue urine to serotonin syndrome

The most famous side effect is also the most harmless. Methylene blue turns urine blue or green for a day or two, and can tint stool, sweat, tears and, after intravenous use, the skin itself. Newcomers to the trend sometimes treat the color as proof the drug is “working”. It is proof of excretion, nothing more.

Beyond the color, the side effects described in the Mayo Clinic and MedlinePlus drug information and the pharmacology reviews fall into a few groups:

• Common and usually mild: nausea, abdominal discomfort, a metallic taste, headache, dizziness, sweating and pain at the injection site.
• Cardiovascular: a rise in blood pressure, occasionally chest discomfort or heart rhythm changes, reflecting its effect on the nitric oxide pathway.
• Neurological: confusion, agitation or tremor, which can be early signs of serotonin syndrome when other serotonin-active drugs are on board.
• Blood: at higher exposures the drug can paradoxically cause the very methemoglobinemia it treats, and in people with G6PD deficiency it can trigger hemolysis, the rupture of red blood cells, leading to anemia and dark urine that is red-brown rather than blue.
• Skin and eyes: phototoxic reactions, especially in newborns exposed during procedures, and increased light sensitivity.

Serotonin syndrome is the reaction clinicians worry about most. It develops within hours, and Mayo Clinic describes a cluster of symptoms: agitation, rapid heartbeat, high blood pressure, dilated pupils, muscle twitching or rigidity, heavy sweating, diarrhea and fever. Severe cases can cause seizures and dangerous overheating. The interaction has been documented with SSRIs, SNRIs, tricyclic antidepressants, MAOIs, some opioids and the cough suppressant dextromethorphan.

One more practical quirk: because the dye absorbs light in the same range that fingertip pulse oximeters read, it can make oxygen saturation look falsely low for several hours. In a hospital, staff know to expect this. At home, a frightening reading could send someone to the emergency department, or worse, mask a real problem.

Who should never take methylene blue without medical supervision?

Some interactions with this drug are inconvenient. Others are emergencies. The groups below appear across the MedlinePlus, Mayo Clinic and StatPearls materials as people for whom methylene blue is either contraindicated or requires specialist judgment.

Anyone taking a serotonin-active medicine. This is the largest group by far. Roughly one in eight American adults takes an antidepressant, and most of those drugs raise serotonin. Add St. John’s wort, tramadol, lithium, triptans for migraine, and dextromethorphan in cold remedies, and the list of everyday products that can combine badly with methylene blue is long. Stopping an antidepressant to make room for the dye would be its own serious risk and is never something to do without the prescribing clinician.

People with G6PD deficiency. This inherited enzyme shortage affects hundreds of millions of people worldwide, most commonly those with ancestry from Africa, the Mediterranean, the Middle East and parts of Asia. Many do not know they have it. In these individuals the drug can destroy red blood cells rather than rescue them.

Pregnant and breastfeeding women. Methylene blue injected into the amniotic sac during older diagnostic procedures was linked to intestinal malformations in infants, and the drug is generally avoided in pregnancy. Its safety in breast milk is not established.

Infants and young children. They are more vulnerable to phototoxic skin injury and to the drug’s own methemoglobin-forming effect.

People with significant kidney disease. The kidneys clear the drug, and reduced function prolongs exposure.

Anyone with a known hypersensitivity to the dye or related compounds.

If you fall into any of these groups and have already tried a product, the right move is not embarrassment but a conversation with a clinician, ideally with the product and your full medication list in hand.

Hospital methylene blue vs. wellness products: a side-by-side look

Much of the confusion in this trend comes from using one name for two very different things. The table lays out the contrast.

Feature	Hospital methylene blue	Trend or grey-market products
Regulatory status	FDA-approved prescription drug (2016) for methemoglobinemia	Not approved for supplement, cognitive or anti-aging use; often labeled for aquariums or “research”
Purity and strength	Pharmaceutical grade, verified concentration	Variable; contaminants and mislabeled strength reported
Who decides the dose	Clinician, based on body weight and lab results	The buyer, guided by social media
Medication check	Full review for serotonin-active drugs and G6PD status	Usually none
Monitoring	Heart rhythm, blood pressure, oxygen levels, blood counts	None
Duration	One or two doses, or a short course	Daily, open-ended
Evidence for the intended use	Decades of clinical consensus	Cell and animal studies; one tiny human imaging study
Emergency backup	Immediate	Whatever the buyer can arrange

Two rows deserve emphasis. The medication check row is where most real-world harm would originate, because serotonin syndrome is the drug’s most predictable severe interaction and the one a lone buyer is least equipped to screen for. The duration row captures the deeper problem: the hospital has decades of experience with brief exposure and essentially none with chronic use.

Compounded or imported oral products advertised for wellness fall into the right-hand column. They are not approved for that purpose and are not intended for self-use; their existence in a bottle does not change their regulatory status. That is a plain description, not a moral judgment about anyone who has bought one.

Common myths about methylene blue, corrected

Viral claims have a way of hardening into common knowledge. These are the ones clinicians hear most often, with what the evidence actually supports.

Myth: “It is just a dye, so it is basically inert.” The staining property is real, but the same molecule inhibits a brain enzyme, constricts blood vessels and carries a formal FDA warning for a life-threatening drug interaction. Food coloring does not do those things.

Myth: “Blue urine means it is working.” Color shows the kidneys are excreting the dye. It says nothing about mitochondria, memory or aging, and it can appear at exposures well below any studied effect.

Myth: “Doctors have used it for a century, so long-term safety is proven.” A century of brief, supervised use is not a record of daily, unsupervised use by healthy people. Those are different exposures, and only the first has data.

Myth: “It is a proven Alzheimer’s treatment that big trials confirmed.” Phase 3 trials of a derivative missed their primary endpoints. The question is open, not answered.

Myth: “Low doses cannot hurt anyone.” Serotonin syndrome and hemolysis in G6PD deficiency are not strictly dose-dependent in the way people imagine, and case reports describe reactions at exposures far below those used in emergency care. Individual susceptibility matters more than the drop count.

Myth: “Aquarium grade is the same chemical, so it is fine.” The chemical name matches; the manufacturing standards do not. Industrial products are not tested for heavy metals or contaminants at the level required for human medicine.

Myth: “It is a natural compound.” Methylene blue was synthesized in a German dye laboratory in 1876. It does not occur in any plant or food.

The pattern behind these myths is a quiet substitution: the genuine, narrow evidence for hospital use is borrowed to vouch for a completely different use. Spotting that swap is the single most useful skill for evaluating any health trend.

Why do experts and influencers disagree so sharply about methylene blue?

People searching this topic often ask why methylene blue is so contested. The answer is less about hidden agendas than about two groups reading the same evidence with different thresholds for action.

Enthusiasts tend to weight mechanism and early data heavily. The mitochondrial biology is real, the animal studies are published, the drug is old and inexpensive to manufacture, and the visible side effect is harmless. From that vantage point, waiting for large trials feels overly cautious.

Clinicians and pharmacologists tend to weight the failure rate of translation and the asymmetry of harm. They have watched dozens of compounds with beautiful mechanisms fail in humans. They also know that for a healthy person the ceiling of benefit is speculative while the floor of harm is documented: a patient on sertraline who develops serotonin syndrome gains nothing and risks a great deal. When the population taking a drug is well, the standard of evidence has to rise, not fall.

A second source of friction is the word “supplement”. In the United States a dietary supplement must be a vitamin, mineral, herb, amino acid or similar dietary substance. Methylene blue is a synthetic prescription drug and does not qualify, so products marketed as supplements are operating outside the law that governs supplements. Enthusiasts hear that as bureaucratic gatekeeping; regulators hear it as basic consumer protection.

Finally, both sides sometimes overreach. Skeptics who call the drug useless ignore its genuine hospital record and active research program. Promoters who call it a longevity breakthrough ignore that no human aging trial exists.

The middle ground is not mushy. Methylene blue is a valuable, well-characterized medicine with serious interactions and no established role in healthy adults. Research should continue. Self-dosing should not.

When to see a doctor about methylene blue

Two situations call for professional input, and one of them is urgent.

Seek emergency care immediately if you or someone near you has taken methylene blue in any form and develops:

• Agitation, confusion, restlessness or hallucinations
• Racing heartbeat, very high blood pressure or chest pain
• Muscle twitching, stiffness, tremor or loss of coordination
• Heavy sweating, shivering, fever or a feeling of overheating
• Shortness of breath, blue or gray lips and fingertips
• Dark red-brown urine, yellowing of the skin or eyes, or sudden severe fatigue, which can signal red cell breakdown
• Seizure or collapse

These signs point to serotonin syndrome, drug-induced methemoglobinemia or hemolysis, all of which can worsen quickly and all of which are treatable when caught early. Tell the emergency team exactly what was taken, when, and every other medicine or supplement in use, including antidepressants, cold remedies and St. John’s wort. Bring the product if you can.

Book a routine appointment if you have been taking methylene blue without symptoms and want to continue, or if you are considering it. Useful topics for that conversation include your complete medication list, whether you have ever been tested for G6PD deficiency, any history of kidney disease, pregnancy or plans for pregnancy, and what you are hoping the drug will do. A clinician can explain whether a supervised, approved use applies to you, whether a research trial exists, or whether the goal you have in mind is better served by something with human evidence.

One firm rule sits above everything else on this page: never stop or reduce a prescribed antidepressant or any other medicine to make room for methylene blue. Abrupt changes to psychiatric medicines carry their own well-documented risks, and every decision about adding, changing or stopping a drug belongs with the clinician who prescribes it.

Frequently asked questions

What is methylene blue used for?

In hospitals, methylene blue is used mainly as an antidote for methemoglobinemia, a condition in which chemically altered hemoglobin cannot deliver oxygen. Intensive care teams also give it as a rescue treatment for severe low blood pressure after cardiac surgery or in septic shock, and surgeons use it as a dye to trace ureters, find leaks and map lymph nodes. Every one of these uses is intravenous, calculated by weight and monitored.

Is methylene blue safe to take daily?

No study has tested daily methylene blue in healthy adults over months or years, so its long-term safety is unknown. Existing safety data comes from one or two hospital doses or short research courses. Known concerns with repeated exposure include monoamine oxidase inhibition, light sensitivity, tissue accumulation and blood pressure effects. Any regular use should be a decision made with a clinician who has reviewed your medications and, where relevant, your G6PD status.

Is methylene blue harmful to humans?

It can be, depending on the person, the amount and what else they are taking. The most serious documented harm is serotonin syndrome when methylene blue is combined with antidepressants and other serotonin-active drugs. People with G6PD deficiency risk hemolysis, and high exposures can paradoxically cause methemoglobinemia. For most people receiving a supervised hospital dose, side effects are mild, but the same molecule taken unsupervised carries real, predictable risks.

Why is methylene blue so controversial?

The disagreement comes from reading the same evidence with different standards. Enthusiasts emphasize the genuine mitochondrial biology, animal studies and long hospital history. Clinicians emphasize that mechanism-based hopes usually fail in human trials, that healthy people have little to gain and documented harms to risk, and that products sold for wellness are not approved or purity-tested. Both agree the drug is valuable in hospitals; they differ on whether that justifies self-use.

What are the main methylene blue side effects?

The most common effect is harmless blue-green urine, sometimes with tinted stool, sweat or skin. Nausea, metallic taste, headache, dizziness and a rise in blood pressure are also reported. Serious reactions include serotonin syndrome when combined with antidepressants, hemolysis in people with G6PD deficiency, drug-induced methemoglobinemia at high exposures, and phototoxic skin reactions, particularly in infants. It can also make pulse oximeter readings falsely low for several hours.

Does methylene blue really have benefits for the brain?

The evidence is preliminary. Animal studies show improved memory and reduced damage after experimental stroke, and one small human imaging study of about 26 volunteers found increased brain activity and modest memory gains after a single dose. Large trials of a modified derivative in Alzheimer’s disease did not meet their primary goals. No study shows that healthy adults taking methylene blue regularly think better or lower their dementia risk.

Can I take methylene blue if I am on an antidepressant?

This combination is the one clinicians worry about most. Methylene blue inhibits monoamine oxidase A, and when paired with SSRIs, SNRIs, tricyclics, MAOIs, tramadol, lithium, triptans or dextromethorphan it can cause serotonin syndrome, a potentially life-threatening reaction. The FDA issued a formal warning about this in 2011. Never stop or adjust an antidepressant to accommodate methylene blue; discuss any interest in the drug with the clinician who prescribes your medicine.

Is methylene blue a dietary supplement?

No. Under U.S. law a dietary supplement must be a vitamin, mineral, herb, amino acid or similar dietary substance, and methylene blue is a synthetic prescription drug first made in a dye laboratory in 1876. Products marketed as supplements or for aquarium and research use are not approved for human wellness purposes, are not manufactured to pharmaceutical purity standards, and are not intended for self-use.

Does methylene blue slow aging or extend lifespan?

Not according to any human evidence. In cultured cells and some mouse studies, methylene blue improved mitochondrial function and reduced markers of cellular aging, which is where the longevity claim originates. No trial in people has measured lifespan, healthspan or validated aging biomarkers. Many compounds with similar results in mice have failed to help humans, and the drug’s benefit in cells reverses into harm at higher concentrations.

Why does methylene blue turn urine blue, and is that dangerous?

The kidneys excrete the dye largely unchanged, and its intense color shows up in urine for a day or two after a dose. This is expected and harmless, and it is not a sign the drug is producing any benefit. Urine that turns dark red-brown rather than blue-green, especially alongside fatigue, yellowed skin or shortness of breath, is different and can signal red blood cell breakdown that needs urgent medical attention.

References

• Methylene Blue: StatPearls, NIH National Library of Medicine
• Methylene Blue: Revisited: Journal of Anaesthesiology Clinical Pharmacology (PMC, NIH)
• Methemoglobinemia: MedlinePlus Medical Encyclopedia
• Glucose-6-phosphate dehydrogenase deficiency: MedlinePlus Medical Encyclopedia

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.